Drugs / 68Ga-NNS309
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07630961 | Jun 2026 → Jan 2028 expected | breast lobular carcinoma, colorectal cancer, hormone receptor-positive breast cancer, non-small cell lung carcinoma +3 | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07261631 | Nov 2025 → May 2029 expected | colorectal cancer, invasive ductal and lobular carcinoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma +2 | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NNS309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07630961 ↗ |
| Modality | Diagnostic / imaging agent | “Diagnostic investigational radiopharmaceutical” NCT07261631 ↗ |